Nucleophosmin 1(NPM1)mutation is a core molecular marker in adult acute myeloid leukemia(AML)and an ideal target for as-sessing subclinical disease burden(i.e.,minimal residual disease[MRD]).This mutation has a significant clinical value in disease classification,treatment selection,and prognosis evaluation.In this review,we integrate the latest research advances and discuss the clinical applicability of targeted therapies,chemotherapy combined with anti-CD33 monoclonal antibodies,and allogeneic hematopoietic stem cell transplanta-tion(allo-hematopoietic stem-cell transplantation).This review highlights the importance of dynamic MRD monitoring to optimize long-term disease management.We particularly focus on the mechanisms of drug resistance in NPM1-mutated AML(e.g.,B-cell lymphoma 2[BCL-2]/myeloid cell leukemia 1[MCL-1]imbalance and metabolic adaptations)and characteristics of the Chinese population(mutation fre-quency,co-mutation profiles,and treatment response).This review aims to provide clinicians with a stratified diagnosis and treatment framework for NPM1-mutated AML as well as theoretical foundations for future research directions.

Nucleophosmin 1(NPM1)mutation is a core molecular marker in adult acute myeloid leukemia(AML)and an ideal target for as-sessing subclinical disease burden(i.e.,minimal residual disease[MRD]).This mutation has a significant clinical value in disease classification,treatment selection,and prognosis evaluation.In this review,we integrate the latest research advances and discuss the clinical applicability of targeted therapies,chemotherapy combined with anti-CD33 monoclonal antibodies,and allogeneic hematopoietic stem cell transplanta-tion(allo-hematopoietic stem-cell transplantation).This review highlights the importance of dynamic MRD monitoring to optimize long-term disease management.We particularly focus on the mechanisms of drug resistance in NPM1-mutated AML(e.g.,B-cell lymphoma 2[BCL-2]/myeloid cell leukemia 1[MCL-1]imbalance and metabolic adaptations)and characteristics of the Chinese population(mutation fre-quency,co-mutation profiles,and treatment response).This review aims to provide clinicians with a stratified diagnosis and treatment framework for NPM1-mutated AML as well as theoretical foundations for future research directions.

Objective To evaluate the interventional therapeatic efficacy of ureteral stricture or obstruction with two ways of percutaneous renal puncture and via urethra simultaneously.Methods 131 patients with ureteral stricture or obstruction were treated with both percutaneous renal puncture and via urethra.Results 149 ureters in 125 patients with benign ureteral stricture were treated with stents in this way,123 patients(149 ureters) were successful and 2 cases failed.9 ureters in 6 patients with malignant ureteral stricture or obstruction were treated with stents successfully.All patients were followed-up for 6 to 120 months,the clinical symptoms of patients were relieved or disappeared,and the infection was controlled,and the uretral obstruction wasn't noticed.Conclusion The treatment of ureteral strictures with percutaneous renal puncture in combination with via urethra is effective,easy and safe.